Please note that following on from information provided to NICE by the company in October 2016, the appraisal of Nintedanib for previously treated metastatic colorectal cancer [ID1030] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1030

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
23 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in October 2016, the appraisal of Nintedanib for previously treated metastatic colorectal cancer [ID1030] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
22 November 2016 Suspended. The Department of Health has asked us to carry out a Single Technology Appraisal (STA) of nintedanib within its marketing authorisation for colorectal cancer. The company have advised that the pivotal study failed to meet one of its co-primary end points and they will not be seeking regulatory approval from the European Medicines Authority for this indication. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, we will continue to monitor any development and will update interested parties if the situation changes
22 July 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual